Covering GLP-1s is really something that needs to at least be talked about by employers because its so prevalent in the industry right now, said Julie Stich, vice president of content at the International Foundation of Employee Benefit Plans (IFEBP)
The science behind peptide therapy is still emerging, and some applications are currently based on early-stage clinical research
Nissen, who served on the trials academic executive committee
GLP-1s, by reducing appetite, can unintentionally reduce protein intake
J Neurol 259(5):886894 Waisbourd M et al (2011) OCT assessment of morphological changes of the optic nerve head and macula in idiopathic intracranial hypertension
A Surgeons Perspective: Where IV Therapy Fits in a Real Weight Loss Plan At BodEvolve Bariatric, the philosophy has always been that real, lasting weight loss requires addressing the whole patient